Caristo's AI technology predicts heart attack risk for
employee wellness initiative from respected centre of
excellence
OXFORD,
England and SURREY,
England , April 23, 2024 /PRNewswire/
-- Surrey Cardiovascular Clinic (SCVC), Southern England's leading centre of
excellence for the prevention and treatment of cardiovascular and
cancer issues, has partnered with Imaging provider VCL SURREY and Caristo Diagnostics,
a leading cardiac disease diagnostics company, to offer the novel
CaRi-Heart® AI technology to predict patients' risk of
developing potentially fatal coronary artery disease.
SCVC will provide the CaRi-Heart AI-based cardiac
assessment as a central part of the organisations 's employee
wellness initiative for UK employers. Designed to provide
industry-leading preventative care for employees and directors, the
programme includes a package of advanced health screening tests
delivered in SCVC's one-stop clinical diagnostic centre (CDC). In
combination with the programme's other tests, Cari-Heart provides
the ability to predict future heart attacks and atherosclerosis
many years before symptoms occur.
"It's well known that the earlier a patient at risk from heart
disease, cancer and other common medical conditions can be
identified, the more effective the prevention strategies become –
yet much of healthcare around us remains largely reactive, not
proactive," said Edward Leatham, MA Cantab, MBBS, MD, MRCP,
director and founder of SCVC. "UK employers are eager for new
options to keep their workers healthier longer, and we are excited
to provide them our state-of-the-art health screening programme,
featuring CaRi-Heart, the validated, individualised predictor of
future cardiac events."
An estimated 1 million adults in the UK present with chest pain
every year1. Many will undergo a coronary computed
tomography angiography (CCTA) scan to diagnose coronary artery
disease caused by plaques that narrow or block the arteries that
supply blood to the heart. However, three quarters of these
patients undergoing CCTAs will display no clear sign of significant
narrowing and would traditionally be seen as low risk of having a
heart attack Yet, there are twice as many deaths or cardiac events
in these "low risk" patients than in those identified as
high-risk.2 A primary cause of these events is coronary
inflammation, a crucial risk factor previously unseen in routine
CCTAs.
Now for the first time, coronary inflammation is detectable in
routine CCTAs using Caristo's CaRi-Heart technology. Based
on research originated at the University of
Oxford, CaRi-Heart is a pioneering AI technology that
predicts heart attack risk by assessing coronary inflammation and
integrating plaque and clinical risk factors such as cholesterol
levels. The technology provides a non-invasive Fat Attenuation
Index ScoreTM (FAI-ScoreTM) as a patented
biomarker for coronary inflammation. Research studies have shown
that an abnormal FAI-Score is associated with a 20-fold increased
risk of fatal heart attack and 6 times higher risk for major
adverse cardiac events (MACEs)2. Based on the FAI-Score,
CaRi-Heart predicts a patient's absolute risk of a fatal
cardiac event over the next 8-10 years.
"Early diagnosis and interventions have the potential to
significantly improve health outcomes for thousands of patients at
risk of coronary artery disease. We are pleased to announce our
partnership with Surrey Cardiovascular Clinic and their imaging
partner VCL Surrey to enhance accessibility to CaRi-Heart
technology for employees throughout the UK," said Frank Cheng, CEO of Caristo Diagnostics.
The CaRi-Heart technology is currently in clinical use in
various NHS and private hospitals in the UK, as well as within the
EU and Australia.
About Caristo Diagnostics
Caristo
Diagnostics is a global leader in cardiac and vascular
disease diagnostics and risk prediction. Founded in 2018 as a
spin-out company from the University of
Oxford, the world's #1 research university, Caristo has
developed a portfolio of imaging-based and AI-assisted platforms
that can be applied to aid the prediction and diagnosis of heart
attack, stroke, and diabetes. Caristo was highlighted by
Nature in 2020 as one of the most exciting science-based
companies to have emerged from academic labs. Find Caristo online
on its website, LinkedIn and X.
About Surrey Cardiovascular Clinic
SCVC was founded in
2006 by cardiologists Edward Leatham
and Peter Clarkson, based on the
concept that in the fast-moving area of cardiovascular medicine
there needed to be an easily accessible centre of excellence in the
South East of England, positioned
outside hospitals. It brings together a multidisciplinary team of
professionals and administration required for modern care.
About Virtual Cath Lab (VCL)
VCL was founded in 2019
by cardiologists Edward Leatham and
Michael Hickman specifically to
provide advanced one stop imaging solution to clinical diagnostic
centres and remove barriers for clinicians to access world class
imaging AI technology. VCLs first site is hosted by the Surrey
Cardiovascular clinic in Guildford
1
https://www.bhf.org.uk/what-we-do/news-from-the-bhf/news-archive/2024/january/act-on-mystery-chest-pain-to-reduce-risk-of-heart-attack
2
– ORFAN data presented at American Heart Association Late Breaking
Science Session 2023
Logo:
https://mma.prnewswire.com/media/2394804/Caristo_Logo.jpg
Logo: https://mma.prnewswire.com/media/2394805/SCVC_Logo.jpg
Caristo Diagnostics contact:
Frank Cheng, CEO, Caristo
Diagnostics
Frank.Cheng@caristo.com
View original
content:https://www.prnewswire.co.uk/news-releases/surrey-cardiovascular-clinic-and-caristo-diagnostics-launch-employee-heart-wellness-and-disease-prevention-program-for-uk-employers-302124584.html